Alavi Mehran, Hamidi Mehrdad
Department of Nanobiotechnology, Faculty of Science, Razi University, Kermanshah, Iran.
Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC), Zanjan, Iran.
Drug Metab Pers Ther. 2019 Feb 1;34(1):dmpt-2018-0032. doi: 10.1515/dmpt-2018-0032.
Considerable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer. Recently, drug delivery systems by LNPs are an emerging technology with numerous advantages over conventional liposomes and chemotherapy using free drug treatment of cancer. These properties are biocompatibility, controlled and sustained release of anti-tumor drugs, and lower toxicity. Valuable experiments on these drug delivery systems offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. LNPs have been presented with high functionality in chemotherapeutic targeting of breast and prostate cancer. The basis for this targeting behavior has been shown to be both passive and active targeting. The main objective of this review was an overview of the current position of the liposome-based drug delivery systems in targeted anticancer chemotherapy.
在过去几十年中，用于癌症治疗的注射用药物递送系统的应用有了长足的发展。这些改进包括脂质体、脂质纳米颗粒（LNPs）以及其他带有或不带有大分子缀合物的纳米颗粒。例如，聚乙二醇修饰的脂质体阿霉素（多美素）是首个具有抗癌作用且被美国食品药品监督管理局批准的脂质体，而艾日布林（负载紫杉醇的修饰白蛋白纳米颗粒）最近被证实可用于治疗乳腺癌。近来，LNPs药物递送系统是一项新兴技术，与传统脂质体和使用游离药物治疗癌症的化疗相比具有众多优势。这些特性包括生物相容性、抗肿瘤药物的控释和缓释以及较低的毒性。对这些药物递送系统进行的有价值的实验为多药耐药性癌症提供了更好的治疗方法，且降低了心脏毒性。LNPs在乳腺癌和前列腺癌的化疗靶向中已表现出高功能性。这种靶向行为的基础已被证明包括被动靶向和主动靶向。本综述的主要目的是概述基于脂质体的药物递送系统在靶向抗癌化疗中的当前地位。
